Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine (nab-P plus G) versus FOLFIRINOX (FFX) in first-line treatment of advanced pancreatic adenocarcinoma (PDAC) in a US community oncology setting.

被引：0

作者：

Braiteh, Fadi S.

Patel, Manish

Parisi, Monika

Ni, Quanhong

Park, Si Yeon

Faria, Claudio

机构：

[1] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[2] Celgene, Summit, NJ USA

[3] Celgene Corp, Summit, NJ USA

[4] Ohio State Univ, Columbus, OH 43210 USA

来源：

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.433

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

433

引用

页数：1